Assembly Biosciences, Inc.

NASDAQ:ASMB

Biotechnology

Healthcare
$22.39 +0.66%

+$0.16 today

Market cap
$458.48M
Beta
1.08
P/E (TTM)
-64.4
EPS (TTM)
-$0.38
52W Low $16.50High $39.71

Volume 0.49M

Average 0.17M

ASMB Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Assembly Biosciences, Inc.NASDAQ: ASMB

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $4.68M rose 3.9% year over year, behind the +10.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 13.6% from the prior quarter. Over 3 fiscal years it compounded at -6.4% a year.

Context

  • Selling, general & admin amounted to 27.1% of revenue in FY2025, down 36.0 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $118.84M (+506.1%) for the fiscal year ending Dec 2026, a step up from the +8.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.68M-13.6% QoQ
Last fiscal yearDec 2025
$19.61M+8.9% YoY
LTMMar 2026
$19.78M+10.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.9%+263.2%+259.4 pp
1 year+8.9%+506.1%+497.2 pp
3-year CAGR-6.4%+84.2%+90.7 pp
5-year CAGR+63.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
19.61M USD
Year-over-year change
+8.9%
4-year CAGR
-9.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ASMB compares with its peers on the latest reported figures

  • ASMB's LTM Mar 2026 selling, general & admin of $19.78M is the 4th highest of the 6 companies compared; the peer median is $30.28M.
  • Its year-over-year change of +10.8% is the 2nd highest of 5, against a peer median of -29.7%.
  • Selling, general & admin amounts to 27.8% of revenue for ASMB, versus a peer median of 55.3%.
ASMB Competitors Peer median
Selling, General & Admin for ASMB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$69.19M ——105.6%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$38.28M -25.4%-1.1%55.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$30.28M -34.0%-12.3%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$19.78M +10.8%-6.4%27.8%
ABUSArbutus Biopharma CorporationLTM Mar 2026$15.94M -39.5%-3.8%8.3%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$10.4M +38.2%+6.9%—
Peer median (excluding ASMB) $30.28M-29.7%-2.5%55.3%

Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.25M07.16M28.52M72.3M
Cost of Revenue069.08M48.9M55.93M129K
Gross Profit6.25M(69.08M)(41.74M)(27.41M)72.17M
Gross Margin100.0%—-582.7%-96.1%99.8%
Research & Development68.52M69.98M48.9M55.93M64.81M
Selling, General & Admin28.78M23.93M22.91M18.01M19.61M
Operating Expenses138.94M25.03M22.91M18.01M84.42M
Depreciation & Amortization466K498K450K129K129K
EBITDA(90.58M)(92.52M)(60.75M)(39.72M)(5.99M)
EBITDA Margin-1448.4%—-848.0%-139.3%-8.3%
Operating Income(132.69M)(94.11M)(64.65M)(45.42M)(12.12M)
Operating Margin-2121.7%—-902.5%-159.3%-16.8%
Interest Income302K1.02M3.45M5.57M6M
Interest Expense00000
Other Income / Expenses302K1.02M3.45M5.57M6M
Income Before Tax(132.39M)(93.09M)(61.2M)(39.85M)(6.12M)
Pre-Tax Margin-2116.8%—-854.3%-139.7%-8.5%
Income Tax Expense(2.53M)033K330K0
Net Income(129.86M)(93.09M)(61.23M)(40.18M)(6.12M)
Net Margin-2076.4%—-854.8%-140.9%-8.5%
EPS (Basic)(36.00)(22.82)(13.38)(6.69)(0.55)
EPS (Diluted)(36.00)(22.82)(13.38)(6.69)(0.55)
Weighted Avg Shares3.61M4.03M4.58M6M11.21M
Weighted Avg Shares (Diluted)3.61M4.03M4.58M6M11.21M

Assembly Biosciences, Inc.

NASDAQ:ASMB

Intrinsic Alpha fair value

Locked

Current Price

$22.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.